A prominent drug-pricing watchdog group says that there is substantial uncertainty regarding the health benefits of aducanumab, the much-anticipated experimental therapydeveloped...
The biopharmaceutical sector has exhibited strong momentum in recent years, driven by government initiatives to modernize the drug regulatory pathway and higher investments in...
Healthcare Is Big BusinessWhether your interest is pharma, direct care, or the life sciences industry as a whole you have to admit that healthcare is big business. We spend...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,351.93 | 2,371.25 | 2,346.16 | +14.58 | +0.62% | 1.44M | NASDAQ | |||
| 319.08 | 322.94 | 318.75 | -0.94 | -0.29% | 15.92M | NASDAQ | |||
| 225.31 | 228.79 | 225.05 | -1.11 | -0.49% | 10.55M | NYSE | |||
| 17.99 | 18.06 | 17.95 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 0.02 | 0.00 | 0.00 | 0.00 | +15.98% | 42.53M | OTC Markets | |||
| 116.83 | 119.42 | 116.05 | -0.17 | -0.15% | 9.61M | NYSE | |||
| 2,398.69 | 2,416.41 | 2,390.00 | +17.34 | +0.73% | 1.16M | NASDAQ | |||
| 19.75 | 20.75 | 19.58 | -0.34 | -1.69% | 63.73M | NYSE | |||
| 20.08 | 20.25 | 17.85 | +1.92 | +10.57% | 10.89M | NYSE | |||
| 17.50 | 17.69 | 16.78 | +0.96 | +5.80% | 913.26K | NASDAQ | |||
| 18.21 | 18.99 | 18.15 | -0.13 | -0.71% | 446.81K | NYSE | |||
| 28.19 | 28.28 | 28.07 | +0.02 | +0.07% | 97.64K | NYSE | |||
| 13.50 | 14.00 | 12.38 | +0.87 | +6.87% | 379.41K | OTC Markets | |||
| 67.33 | 67.96 | 66.58 | +0.44 | +0.66% | 8.08M | NYSE | |||
| 137.85 | 138.69 | 136.29 | +1.85 | +1.36% | 6.89M | NASDAQ |
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.